

Jeffrey A Longmate

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2811401/jeffrey-a-longmate-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

4,248
citations

34
h-index

65
g-index

65
ext. papers

4,563
ext. citations

5
avg, IF

4.55
L-index

#	Paper	IF	Citations
65	Polygenic control of susceptibility to murine systemic lupus erythematosus. <i>Immunity</i> , 1994 , 1, 219-29	32.3	435
64	Speed congenics: a classic technique in the fast lane (relatively speaking). <i>Trends in Immunology</i> , 1997 , 18, 472-7		277
63	Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 304-10	15.1	277
62	Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. <i>Cancer Research</i> , 2004 , 64, 962-8	10.1	252
61	Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. <i>Molecular and Cellular Biology</i> , 2003 , 23, 2362-78	4.8	238
60	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 777-83	3.5	229
59	The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. <i>American Journal of Surgical Pathology</i> , 1997 , 21, 1409-19	6.7	165
58	Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. <i>Blood</i> , 2009 , 113, 6465-76	2.2	114
57	Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. <i>Cancer</i> , 2004 , 100, 2125-31	6.4	103
56	Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. <i>PLoS Pathogens</i> , 2014 , 10, e1004524	7.6	87
55	The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. <i>Clinical Cancer Research</i> , 2005 , 11, 4444-50	12.9	86
54	Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. <i>Journal of Virology</i> , 2001 , 75, 3048-52	6.6	84
53	Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. <i>Human Immunology</i> , 2003 , 64, 440-52	2.3	83
52	Complexity and power in case-control association studies. <i>American Journal of Human Genetics</i> , 2001 , 68, 1229-37	11	82
51	Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. <i>Journal of Infectious Diseases</i> , 2007 , 195, 633-44	7	81
50	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 19-26	3.5	80
49	The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 433-7	3.3	78

48	Multiplex inheritance of component phenotypes in a murine model of lupus. <i>Mammalian Genome</i> , 1999 , 10, 176-81	3.2	78
47	Evidence for X-chromosomal schizophrenia associated with microRNA alterations. <i>PLoS ONE</i> , 2009 , 4, e6121	3.7	76
46	A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. <i>Anti-Cancer Drugs</i> , 2009 , 20, 179-84	2.4	75
45	CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. <i>Journal of Immunology</i> , 2003 , 170, 3401-7	5.3	75
44	A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. <i>Journal of Virology</i> , 2013 , 87, 1322-32	6.6	74
43	Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1294-304	7	74
42	Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. <i>Human Immunology</i> , 2004 , 65, 476-85	2.3	73
41	Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. <i>Journal of Virology</i> , 2004 , 78, 3965-76	6.6	65
40	Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. <i>Clinical Cancer Research</i> , 2004 , 10, 461-7	12.9	64
39	Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. <i>Journal of Infectious Diseases</i> , 2008 , 197, 25-33	7	57
38	A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. <i>Clinical Cancer Research</i> , 2006 , 12, 1556-63	12.9	56
37	MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. <i>Blood</i> , 2017 , 129, 114-125	2.2	52
36	Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1410-21	7	42
35	Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. <i>Journal of Virology</i> , 2011 , 85, 2878-90	6.6	40
34	Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. <i>Cancer Research</i> , 2004 , 64, 5407-14	10.1	40
33	Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. <i>Blood</i> , 2004 , 104, 847-56	2.2	40
32	Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 317-22	2.7	36
31	Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. <i>Vaccine</i> , 2005 , 23, 3453-68	4.1	33

30	A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 835-43	3.5	31
29	Identification of high risk DISC1 protein structural variants in patients with bipolar spectrum disorder. <i>Neuroscience Letters</i> , 2010 , 486, 136-40	3.3	27
28	Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. <i>Journal of Immunology</i> , 2003 , 171, 4028-39	5.3	26
27	Simultaneous reconstitution of multiple cytomegalovirus-specific CD8+ cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. <i>Journal of Infectious Diseases</i> , 2005 , 191, 977-84	7	26
26	Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2001 , 184, 256-67	7	25
25	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 126-134	8.9	25
24	Variations of dose and electrode spacing for rat breast cancer electrochemical treatment. <i>Bioelectromagnetics</i> , 2001 , 22, 205-11	1.6	24
23	Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 890-902	4.7	22
22	Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. <i>Transplant International</i> , 2011 , 24, 920-31	3	21
21	In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. <i>Experimental Hematology</i> , 2006 , 34, 497-507	3.1	21
20	Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. <i>Gynecologic Oncology</i> , 2000 , 77, 433-8	4.9	18
19	Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 22-8	3.5	17
18	Toxicity equivalence range design (TEQR): a practical Phase I design. <i>Contemporary Clinical Trials</i> , 2011 , 32, 114-21	2.3	15
17	Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. <i>Clinical Lung Cancer</i> , 2011 , 12, 33-7	4.9	15
16	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. <i>Blood</i> , 2011 , 118, 2159-69	2.2	14
15	Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity. <i>Journal of Infectious Diseases</i> , 2003 , 188, 908-18	7	14
14	Analysis of imprinting in mice with uniparental duplication of proximal chromosomes 7 and 15 by use of a custom oligonucleotide microarray. <i>Mammalian Genome</i> , 2004 , 15, 199-209	3.2	13
13	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 126-34	8.9	11

12	A phase II trial of gefitinib and pegylated IFN α in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011 , 16, 494-9	4.2	9
11	Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. <i>Clinical Lung Cancer</i> , 2004 , 6, 102-7	4.9	9
10	Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4876-80	2.2	9
9	Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2016 , 100, 210-6	1.8	9
8	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 353-9	3.5	8
7	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 327-32	3.5	8
6	Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up. <i>Gynecologic Oncology</i> , 1999 , 75, 419-26	4.9	8
5	Three ways of combining genotyping and resequencing in case-control association studies. <i>PLoS ONE</i> , 2010 , 5, e14318	3.7	7
4	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 283-9	3.5	7
3	Loss of T cell progenitor checkpoint control underlies leukemia initiation in Rag1-deficient nonobese diabetic mice. <i>Journal of Immunology</i> , 2013 , 190, 3276-88	5.3	3
2	Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). <i>Clinical Lung Cancer</i> , 2021 , 22, 541-548	4.9	3
1	Untenable dosing: A common pitfall of modern DLT-targeting Phase I designs in oncology. <i>Current Problems in Cancer</i> , 2020 , 44, 100583	2.3	2